Independent global B2B platform
Expert in API & CDMO market
Direct contact between you and supplier

Find, compare & contact
Ganirelix Acetate API Manufacturers & Suppliers

Real trade data
teaser-1024x654-1
Contact suppliers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Ganirelix Acetate is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Ganirelix Acetate or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Ganirelix Acetate API 124904-93-4?

Description:
Here you will find a list of producers, manufacturers and distributors of Ganirelix Acetate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Ganirelix Acetate 
Cas Number:
124904-93-4 
DrugBank number:
DB06785 
Unique Ingredient Identifier:
Org 37462;RS 26306;SML0241

About Ganirelix Acetate

Ganirelix Acetate is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist used in assisted reproduction. It modulates the hypothalamic-pituitary-gonadal axis, causing rapid, profound, and reversible suppression of endogenous gonadotropins. Indicated for controlled ovarian hyperstimulation, Ganirelix Acetate is key in preventing premature luteinizing hormone (LH) surges during assisted reproductive techniques (ART). It operates by competitively blocking GnRH receptors on the pituitary gonadotroph and subsequent transduction pathways, effectively suppressing the secretion of pituitary LH and FSH. This drug has a significant impact on the management of fertility treatments, offering an alternative to GnRH agonists by avoiding initial gonadotropin release and associated side effects.

??